NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

Company Overview

NewAmsterdam Pharma, Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation. These investigational compounds are designed to improve glycemic control, support weight management and reduce cardiometabolic risk factors. NewAmsterdam Pharma’s programs emphasize oral delivery formats and aim to provide differentiated safety and efficacy profiles compared with existing therapies.

Headquartered in the United States, NewAmsterdam Pharma leverages a network of research collaborations with academic institutions and industry partners to accelerate its discovery and development activities. The company’s strategic alliances support advancement of its clinical candidates through regulatory milestones and position it to pursue global development and commercialization opportunities for patients with metabolic disorders.

Key Stats

• Today's Range: $29.10 to $31.00
• 50-Day Range: $28.43 to $36.25
• 52-Week Range: $16.78 to $42.00
• Volume: 885,491 shs
• Average Volume: 831,866 shs
• Market Capitalization: $3.44 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $48.00
• Consensus Rating: Moderate Buy

NewAmsterdam Pharma Stock Analysis - MarketRank™

NewAmsterdam Pharma scored higher than 78% of companies evaluated by MarketBeat, and ranked 130th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

NewAmsterdam Pharma has a consensus price target of $48.00, representing about 60.6% upside from its current price of $29.88.

Amount of Analyst Coverage

NewAmsterdam Pharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($1.89) to ($1.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of NewAmsterdam Pharma is -17.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NewAmsterdam Pharma is -17.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NewAmsterdam Pharma has a P/B Ratio of 5.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.44% of the float of NewAmsterdam Pharma has been sold short.

Short Interest Ratio / Days to Cover

NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.74.

Change versus previous month

Short interest in NewAmsterdam Pharma has recently decreased by 4.53%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NewAmsterdam Pharma does not currently pay a dividend.

Dividend Growth

NewAmsterdam Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.83

News Sentiment

NewAmsterdam Pharma has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for NewAmsterdam Pharma this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for NAMS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NewAmsterdam Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $38,211,967.00 in company stock.

Percentage Held by Insiders

20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NAMS Stock Analysis - Frequently Asked Questions

How have NAMS shares performed this year?

NewAmsterdam Pharma's stock was trading at $35.08 on January 1st, 2026. Since then, NAMS shares have decreased by 14.8% and is now trading at $29.8810.

How were NewAmsterdam Pharma's earnings last quarter?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) posted its quarterly earnings results on Wednesday, February, 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.23. The company earned $0.19 million during the quarter, compared to analyst estimates of $0.92 million. NewAmsterdam Pharma had a negative trailing twelve-month return on equity of 26.67% and a negative net margin of 906.22%.

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's top institutional investors include Medicxi Ventures Management Jersey Ltd (2.33%), Bank of New York Mellon Corp (0.33%), Peregrine Capital Management LLC (0.16%) and Swedbank AB (0.09%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Johannes Jacob Piete Kastelein, Douglas F Kling, Louise Frederika Kooij, Louis G Lange and Juliette Berangere Audet.
View institutional ownership trends.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NewAmsterdam Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

• Last Earnings: 2/18/2026
• Today: 5/05/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NAMS
• CIK: 1936258
• Web: www.newamsterdampharma.com
• Phone: 352062971
• Fax: N/A
• Employees: 4
• Year Founded: 2019

Price Target and Rating

• Average Price Target for NewAmsterdam Pharma: $48.00
• High Price Target: $57.00
• Low Price Target: $37.00
• Potential Upside/Downside: +60.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$203.82 million
• Net Margins: -906.22%
• Pretax Margin: -905.74%
• Return on Equity: -26.67%
• Return on Assets: -24.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.88
• Quick Ratio: 7.88

Sales & Book Value

• Annual Sales: $22.50 million
• Price / Sales: 152.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.97 per share
• Price / Book: 5.01

Miscellaneous

• Outstanding Shares: 114,970,000
• Free Float: 91,014,000
• Market Cap: $3.44 billion
• Optionable: Optionable
• Beta: 0.02